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Abstract 
Glioblastoma multiforme (GBM) is the most common type of primary brain tumor, and current treatment 
regimens are only marginally effective. One of the most vexing and malignant aspects of GBM is its 
pervasive infiltration into surrounding brain tissue. This review describes the role of the Wilms tumor 1 
gene (WT1) and its relationship to GBM. WT1 has several alternative splicing products, one of which, the 
KTS+ variant, has been demonstrated to be involved in the transcriptional activation of a variety of 
oncogenes as well as the inhibition of tumor suppressor genes. Further, this paper will examine the 
relationship of WT1 with CD97, a gene that codes for an epidermal growth factor receptor family member, 
an adhesion G-protein–coupled receptor, thought to promote tumor invasiveness and migration. The 
authors suggest that further research into WT1 and CD97 will allow clinicians to begin to deal more 
effectively with the infiltrative behavior displayed by GBM and design new therapies that target this deadly 
disease. (http://thejns.org/doi/abs/10.3171/2014.9.FOCUS14506) 
 
Glioblastoma multiforme (GBM), a WHO Grade IV glioma, is the most common primary malignancy in the 
central nervous system. GBM is characterized by high degrees of parenchymal invasion, vascularization 
secondary to angiogenesis, necrosis, and de-differentiation. Due to its aggressive nature, GBM carries a 
poor prognosis, with 35.7% survival at 1 year and 4.7% survival at 5 years.26 Currently, the optimal 
treatment paradigm is aggressive resection followed by radiotherapy and concomitant chemotherapy.33 
Despite intensive laboratory and clinical research, only moderate advances have been made in improving 
the quality of life in GBM patients. This suggests that there is a need to build a complete biological profile 
to uncover novel molecular targets that can be employed in future therapies. Recently, our laboratory and 
others have shifted their focus to the Wilms tumor 1 gene (WT1).5–8 WT1 was first isolated in 1990 by 
Haber et al. with their discovery that an internal deletion within an 11p13 zinc finger gene con-tributes to 
the development of Wilms tumor, a pediatric kidney malignancy.10 WT1 was initially thought to be a tumor 
suppressor gene, but subsequent research uncovered its oncogenic role when it was demonstrated that 
WT1 can suppress hTERT gene expression and telomerase activity in clear cell renal cell carcinoma.31 
 
Menssen et al. were the first group to show the expression of WT1 in human GBM. They reported a high 
WT1 expression in 63% of GBM cell lines.21 In the same year, we also reported the expression of WT1 in a 
variety of ovarian and GBM cultured cell lines (Quezado MM, Dechsukhum C, Garrett CT, et al., presented 
at the United States and Canadian Academy of Pathology Annual Meeting, 2000). Since these initial 
descriptions, there has been an expanding interest in connecting WT1 and its oncological effect with GBM. 
This paper will review the studies to date that have analyzed the relationship of WT1 to GBM and describe 
a novel G-protein coupled receptor, CD97, which may play a role in GBM invasion. 
 
Wilms Tumor 1 Gene 
Though WT1 is absent in normal neural tissue, it has been described in cultured neoplastic glial cell lines, 
and further work has indicated high WT1 expression in acute myeloid leukemia and acute lymphoid 
leukemia.7,15 WT1 encodes for a zinc finger family transcription factor located at 11p13 whose physiological 
expression is associated with normal genitourinary embryologic development.1 It has been hypothesized 
that WT1 may exert its oncological effects in a multifaceted modality via an alternative mRNA splicing 
variant that involves the insertion of the 3–amino acid sequence of lysine, threonine, serine (KTS) into the 
active zinc finger region.28 This is in contrast to the KTS− variant, which transcriptionally regulates 
suppression of at least 7 putative tumor suppressor genes and increases expression of 11 reputed 
oncogenes.5 The KTS+ product, on the other hand, has only a limited role in direct transcriptional 
regulation; instead it participates in putative splicing factor interactions and has an association with 
olfactory neuron development.14 
 
GBM and Wilms Tumor 
When WT1 expression was first reported in brain tumors, it was hypothesized that testing for WT1 
expression might not have clinical significance.21 The first laboratory investigation that focused on WT1 
expression in central nervous system malignancies, including GBM, found WT1 expression in most of these 
tumors; yet there were no mutations affecting the zinc fingers of the gene product in tumors expressing 
WT1.9 Though this appeared to indicate that WT1 expression might not have clinical relevance to the 
molecular etiology of brain tumors, these results nonetheless ignited a novel interest in the relationship of 
WT1 to central nervous system tumors. A few years later, Oji et al. were able to show that the WT1 protein 
expression was significantly greater in high-grade tumors than in low-grade tumors and that treatment with 
WT1 antisense oligomers specifically inhibited GBM cell lines.24 This study, coupled with later confirmation 
from immunohistochemical tests that demonstrated WT1 expression in GBM cells, high-lighted its potential 
as a target for immunotherapy.12,23 This differential expression of WT1 in high-grade brain tumors has 
recently been validated in an in vivo study analyzing human gliomas, which included 442 glioblastomas, 303 
astrocytomas, 41 oligodendrogliomas, and 43 oligoastrocytomas.27 The results showed that WT1 expression 
in brain tumors increased with WHO grade, older age, and absence of IDH1 mutation.27 
 
The introduction of a WT1-based vaccine in clinical trials was first described by Oka et al. in 2004.13,25 The 
authors reported the effects of the vaccine on breast cancer, lung cancer, and leukemia in 26 patients, 
reporting tumor regression and no toxicity as a result of the drug. The same group recently published data 
on a Phase II clinical trial that included 21 patients who received WT1 peptide vaccination for recurrent 
GBM.15 Preliminary data showed that patients with WT1/HLA-A*2402 positivity who received WT1 
immunotherapy showed a favorable outcome when compared with patients treated with a standard 
chemotherapy protocol.15 In a follow-up study analyzing the same GBM patient population, the authors 
reported that WT1 expression can be used as a prognostic marker in determining progression-free survival 
after immunotherapy and that patients with intermediate WT1 expression levels may have the best 
outcomes.4 
 
One possible mechanism of action of a WT1-based vaccination could lie in its suppression of WT1’s 
inactivation of tumor suppressor gene p53 (TP53). This hypothesis was initially tested in p53-null Saos-2 
osteosarcoma cells, and it was revealed that WT1 inhibits p53-mediated apoptosis, which is normally 
induced by chemotherapy, radiation, and overexpression of wild-type p53.20 Clark et al. continued to 
investigate this relationship between WT1 and p53 in GBM by examining the effect of WT1 expression and 
WT1 silencing on p53-mediated cell death and response to radiotherapy.6 Results showed that WT1 
silencing led to GBM cells becoming susceptible to radiation-induced death, suggesting a potential target to 
improve responses to radiotherapy. The relationship of WT1 silencing and chemotherapy was tested in a 
separate study by Chen et al. that revealed similar results; WT1 silencing resulted in increased 
chemotherapeutic response.3 It was reported in follow-up work that there was an interaction between the 
KTS+ isoform of WT1 and wild-type p53, revealing that the potential oncogenic function of WT1 in GBM 
may depend on this splicing variant.7 
 
Additional avenues whereby WT1 promotes tumorigenesis was found in WT1’s relation with Wilms tumor 
1–associated protein (WTAP, also known as pre-mRNA-splicing regulator WTAP). WTAP is a nuclear protein 
that was isolated through a yeast 2-hybrid screen and has been reported to be overexpressed in GBM cell 
lines.16,19 Jin et al. suggested that WTAP may regulate migration and invasion of GBM cells by controlling 
epidermal growth factor signaling.16 The link between WT1 and cancer cell invasion was initially reported 
by Jomgeow et al. in TYK ovarian cancer cell lines, where in vitro experiments demonstrated that WT1 
overexpression led to an increase in cell inva-sion.17 Kijima et al. demonstrated that GBM cell lines with 
downregulated WT1 expression had decreased tumorigenicity in an intracranial in vivo assay.18 Further, 
they suggested that WT1 may play a role in apoptosis as cell lines transfected with anti-WT1 shRNA showed 
upregulation of apoptosis-related genes when compared with control cell lines—supporting a previous 
report that WT1 may be involved in apoptosis in GBM.34 These preliminary studies suggest that the 
oncogenic role WT1 may play in GBM cell proliferation, invasiveness, and survival involves suppressed 
apoptosis. 
 
  
CD97 
Recent research at our institution has focused on another molecule that appears to be involved in 
promoting the invasiveness of GBM through a relationship with WT1, as an apparent target of WT1 
transcriptional activation.5 The CD97 molecule, also known as TM7LN1, is a member of the epidermal 
growth factor–7 transmembrane (EGF-TM7) cell receptor subfamily that mediates cell-cell interactions. 
CD97 is a part of a 6-member family of adhesion G-protein coupled receptors that have been primarily 
reported as expressed on the surface of leukocytes.29 Structurally, CD97 resembles all other EGF-TM7 
receptors, consisting of an extracellular alpha unit, a transmembrane beta unit composed of 7 domains, 
and an intracellular C-terminus. The alpha unit is com-posed of 5 EGF-like domains and a single Arg-Gly-Asp 
motif, which acts as a binding site for several classes of integrins. Alternative splicing of the mRNA 
transcript of the alpha subunit allows 3 isoforms to be generated—EGF (1–5), EGF (1,2,5), and EGF 
(1,2,3,4,5)—which allows binding heterogeneity.30 CD97 has 3 known ligands, which include CD55/decay 
accelerating factor (DAF), chondroitin sulfate, and alpha-beta integrin. CD55/DAF serves as an inhibitor of 
the complement system and binds to the EGF (1,2,5) domain.11,22,30 Chondroitin sulfate proteoglycans are 
components of the extracellular matrix that have a role in cell adhesion, growth, receptor binding, and the 
migration of cells and binding to EGF (1,2,3,4,5) domains.29 Integrins, which are transmembrane receptors 
involved in cell-to-cell adhesion, migration, and signaling, bind to EGF (1,2,5) and EGF (1,2,3,4,5).29 The 
capability of these various isoforms to bind to ligands with complex functions makes CD97 an intriguing 
therapeutic target for cancer treatment, because it raises the possibility that an exogenous small molecule 
might be developed that could inhibit its function. 
 
CD97 was first described in thyroid carcinomas, showing a high expression in undifferentiated anaplastic 
carcinomas.2 Since this initial description in thyroid cancer, further work has found CD97 to be highly 
expressed in pancreatic cancers, colon cancers, and oral squamous cell carcinoma.32 Chidambaram et al. 
were the first to de-scribe CD97 in GBM.5 They showed that CD97 expression was significantly 
downregulated in all 3 GBM cell lines they analyzed after suppression of WT1 expression. They observed 
that decreasing the endogenous expression of CD97 decreased the ability of cells to invade through 
Matrigel, suggesting that CD97 might promote cellular invasiveness. Safaee et al., using human GBM cell 
lines prepared at their institution, revealed through siRNA knockdown that CD97 may play a role in 
invasiveness and migration but not proliferation.30 They reported that patients whose tumors 
overexpressed CD97 had a significantly shorter survival time when compared with those who had tumors 
that showed a downregulation of CD97 using data from the Cancer Genome Atlas database.30 The analysis 
included 212 patients and revealed that patients with upregulation of CD97 had a median survival of 250 
days compared with a median of 500 days for patients with downregulated expression. This preliminary 
study suggests that upregulation of CD97 in GBM patients may confer a poorer prognosis, and future 
studies will help further elucidate this relationship. 
Conclusions 
When WT1 was first reported in brain tumors it was hypothesized that it was unlikely to be of clinical 
significance, but as research has evolved WT1 has been shown to play a significant role in GBM tumor 
biology. WT1 promotion of tumor invasiveness, proliferation, and survival through its interaction with p53, 
WTAP, and CD97 all contribute to its multifaceted oncogenic role. Molecular genetics is opening exciting 
new avenues in the under-standing of difficult-to-treat cancers such as GBM. In an effort to capitalize on 
this ongoing revolution, this paper has summarized the current knowledge concerning WT1 and GBM and 
this gene’s potential role in tumor biology. Moving forward, the authors call upon researchers to continue 
to elucidate the role of the KTS+ WT1 variant in tumorigenesis, further define the interplay between WT1 
and CD97, and continue to develop novel therapies using these new targets. Future studies that will help 
further develop this emerging field of glioblastoma biology include: larger experiments that use human 
tissue to clinically correlate WT1 and CD97 expression and patient out-comes, identification of molecules 
that can inhibit CD97 to see if there is a survival advantage that could lead to therapeutic options for GBM 
patients, investigate WT1 and CD97 expression in recurrent GBM, and a study focusing on the 
microenvironment changes during GBM progression with and without treatment interventions to further 
investigate the multiple effects of CD97 in invasion and growth. 
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